Siva Rayavaram
About Siva Rayavaram
Siva Rayavaram is the Associate Director of Digital Insights & Analytics at Bristol Myers Squibb, with expertise in pharmacovigilance, clinical trial analytics, and data visualization tools.
Title at Bristol Myers Squibb
Siva Rayavaram holds the title of Associate Director, Digital Insights & Analytics at Bristol Myers Squibb. In this role, they are responsible for overseeing the company's digital insights and analytics, providing critical data-driven insights for decision-making processes.
Previous Roles at Bristol Myers Squibb
Before becoming the Associate Director, Siva Rayavaram served as a Principal Analyst at Bristol Myers Squibb from 2015 to 2021. Prior to that, they worked as a SAS Consultant from 2012 to 2015 in Princeton, New Jersey. These roles have contributed to their extensive experience in data analysis and pharmacovigilance.
Educational Background
Siva Rayavaram earned a Master of Science (MS) in Industrial and Physical Pharmacy and Cosmetic Sciences from Long Island University. This program, completed between 2010 and 2012, provided a foundation in pharmaceutical science, which has been instrumental in their professional journey.
Proficiency in Data Visualization Tools
Siva Rayavaram has expertise in utilizing data visualization tools like Spotfire and Tableau for pharmacovigilance and clinical trial analytics. These tools are essential in translating complex data into actionable insights, supporting the safety and efficacy of pharmaceutical products.
Technical Skills and Specializations
Proficient in programming languages and tools such as SAS, SQL, Python, and VBA, Siva Rayavaram also specializes in SDTM standards and vendor oversight within the drug safety and clinical analytics sector. Their technical skill set aids in efficient data management and analysis.
Background in Post-marketing Data Analytics
Siva Rayavaram has a strong background in post-marketing data analytics. This involves monitoring the safety and efficacy of pharmaceutical products after they have been released to the market, ensuring ongoing compliance with regulatory standards, and contributing to post-marketing surveillance.